Chipscreen(688321)2025-01-17 10:00Revenue Projections - The company expects to achieve an annual revenue of approximately 657.85 million yuan in 2024, representing a year-on-year growth of about 25.61%[2]. - The significant increase in revenue is attributed to the substantial growth in sales of the products Sidabone and Siglitazone[5]. Net Loss Forecast - The projected net loss attributable to shareholders for 2024 is approximately 111.43 million yuan, a decrease of about 200.27 million yuan compared to the previous year, reflecting a year-on-year decline of approximately 225.43%[2]. - The expected net loss attributable to shareholders after deducting non-recurring gains and losses for 2024 is approximately 202.90 million yuan, which is a reduction of about 14.60 million yuan compared to the previous year, indicating a year-on-year decrease in loss of about 6.71%[2]. Strategic Decisions - The company has agreed to terminate the exclusive licensing and joint marketing strategic cooperation agreement with Zhejiang Haizheng Pharmaceutical Co., Ltd., resulting in a one-time recognition of approximately 65 million yuan in unamortized licensing fees and related clinical trial costs[5]. - The company decided not to submit the listing application for the monotherapy of Sioronib for third-line and above small cell lung cancer, leading to a full impairment provision of approximately 90 million yuan for the remaining development expenses of this project[5]. Financial Reporting and Risks - The financial data in the performance forecast has not been audited by a registered accountant[2]. - As of the announcement date, the company has not identified any significant uncertainties that may affect the accuracy of this performance forecast[6]. - The forecast data is preliminary and the specific accurate financial data will be based on the officially disclosed audited annual report for 2024[8]. - Investors are advised to pay attention to investment risks related to the forecast[8].